Literature DB >> 25281468

Cancer-related inflammation and treatment effectiveness.

Connie I Diakos1, Kellie A Charles2, Donald C McMillan3, Stephen J Clarke4.   

Abstract

Inflammation is a recognised hallmark of cancer that substantially contributes to the development and progression of malignancies. In established cancers, there is increasing evidence for the roles that local immune response and systemic inflammation have in progression of tumours and survival of patients with cancer. This knowledge provides an opportunity to target these inflammatory responses to improve patient outcomes. In this Review, we examine the complex interplay between local immune responses and systemic inflammation, and their influence on clinical outcomes, and propose potential anti-inflammatory interventions for patients with cancer.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25281468     DOI: 10.1016/S1470-2045(14)70263-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  618 in total

1.  Response.

Authors:  David Goldstein; Daniel Von Hoff
Journal:  J Natl Cancer Inst       Date:  2015-08-06       Impact factor: 13.506

2.  Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer.

Authors:  Yasunori Yoshino; Ayumi Taguchi; Maki Takao; Tomoko Kashiyama; Akiko Furusawa; Masaya Uno; Satoshi Okada; Nao Kino; Toshiharu Yasugi
Journal:  Int J Clin Oncol       Date:  2018-11-30       Impact factor: 3.402

3.  JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.

Authors:  Chunwan Lu; Asif Talukder; Natasha M Savage; Nagendra Singh; Kebin Liu
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

4.  Quality of Life in Patients With Advanced Cancer: Differential Association With Performance Status and Systemic Inflammatory Response.

Authors:  Barry J A Laird; Marie Fallon; Marianne J Hjermstad; Sharon Tuck; Stein Kaasa; Pål Klepstad; Donald C McMillan
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

5.  Glasgow Prognostic Score and Prognosis After Hepatectomy for Hepatocellular Carcinoma.

Authors:  Tomoyuki Abe; Hirotaka Tashiro; Tsuyoshi Kobayashi; Minoru Hattori; Shintaro Kuroda; Hideki Ohdan
Journal:  World J Surg       Date:  2017-07       Impact factor: 3.352

6.  Small GTPase RBJ promotes cancer progression by mobilizing MDSCs via IL-6.

Authors:  Qiuyan Liu; Ha Zhu; Chaoxiong Zhang; Taoyong Chen; Xuetao Cao
Journal:  Oncoimmunology       Date:  2016-12-23       Impact factor: 8.110

7.  Systemic Inflammatory Markers Combined with Tumor-Infiltrating Lymphocyte Density for the Improved Prediction of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.

Authors:  Ryuichiro Sawada; Takashi Akiyoshi; Yusuke Kitagawa; Yukiharu Hiyoshi; Toshiki Mukai; Toshiya Nagasaki; Tomohiro Yamaguchi; Tsuyoshi Konishi; Noriko Yamamoto; Masashi Ueno; Yosuke Fukunaga
Journal:  Ann Surg Oncol       Date:  2021-04-19       Impact factor: 5.344

8.  Clinical significance of traditional clinical parameters and inflammatory biomarkers for the prognosis of patients with spinal chondrosarcoma: a retrospective study of 150 patients in a single center.

Authors:  Kehan Xu; Bo Li; Quan Huang; Dongjie Jiang; Haitao Sun; Nanzhe Zhong; Wei Wan; Haifeng Wei; Jianru Xiao
Journal:  Eur Spine J       Date:  2019-05-04       Impact factor: 3.134

9.  Differential expression of inflammasomes in lung cancer cell lines and tissues.

Authors:  Hui Kong; Yanli Wang; Xiaoning Zeng; Zailiang Wang; Hong Wang; Weiping Xie
Journal:  Tumour Biol       Date:  2015-04-25

Review 10.  Cancer and inflammation.

Authors:  Lance L Munn
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2016-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.